Replies to post #247029 on Biotech Values

[rfj1862]

Cio / Dew Have either of you looked at OMER's Narsoplimab ( OMS721) for Iga Nephropathy
P3 9 mth data due Q3

Seems like the IgAN space is getting a little crowded.

Also narsoplimab inhibits the lectin pathway of complement. While the lectin pathway is involved, IgAN is predominantly driven by alternative pathway activation.